Coronavirus (Covid-19)
A collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.
CORONAVIRUS (COVID-19) VACCINE RESOURCES VACCINE FAQ
-
-
Special Report
SARS-CoV-2 Variants and Vaccines
P.R. Krause and Others
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral variants of concern arouses concern regarding possible escape from vaccine-elicited immunity. Global strategies involving integration of clinical rollout with systematic investigation are presented.
Jun 23 -
Correspondence
Three Covid-19 Vaccine Doses in Transplant Recipients
N. Kamar and Others
Solid-organ transplant recipients receiving immunosuppressive therapy appear to have a poor response to Covid-19 vaccination. A group of 101 consecutive transplant recipients received two doses of the BNT162b2 vaccine 1 month apart and a third dose 2 months after the second dose; 40% had antibodies after the second dose and 68% had antibodies after the third dose.
Jun 23
-
Special Report
SARS-CoV-2 Variants and Vaccines
P.R. Krause and Others
-
-
Original Article
Ad26.COV2.S Vaccine Efficacy against Covid-19
J. Sadoff and Others
Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–critical Covid-19 and 85% against severe–critical Covid-19. Efficacy against the variant first identified in South Africa was 64% against moderate disease and 82% against severe–critical disease.
Jun 10
-
-
-
Correspondence
Vaccination and Household Transmission of SARS-CoV-2
R.J. Harris and Others
In this study involving household contacts of persons with laboratory-confirmed Covid-19, the risk of household transmission was 40 to 50% lower among household contacts of index patients who had received one dose of vaccine 21 days or more before testing positive than among contacts of unvaccinated index patients.
Jun 23
-
Correspondence
Vaccination and Household Transmission of SARS-CoV-2
R.J. Harris and Others
-
-
Original Article
Effectiveness of the BNT162b2 mRNA Vaccine in Israel
N. Dagan and Others
Nearly 600,000 people in a large health care organization were followed after vaccination for infection, hospitalization, and severe Covid-19. Estimated vaccine effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and for the period 7 or more days after the second dose, hospitalization was reduced by 87%. These results were similar to those reported in a randomized trial.
Apr 15
-
Original Article
Effectiveness of the BNT162b2 mRNA Vaccine in Israel
N. Dagan and Others
-
-
Correspondence
Persistence of Antibody after mRNA-1273 Vaccination
N. Doria-Rose and Others
A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months after vaccination. SARS-CoV-2 neutralizing activity was maintained in all the patients through the entire period of follow-up. A half-life of 202 days was determined for the live-virus neutralization activity.
Apr 06
-
Correspondence
Persistence of Antibody after mRNA-1273 Vaccination
N. Doria-Rose and Others
-
-
Correspondence
SARS-CoV-2 Vaccine and Infection in Health Workers
J. Keehner and Others
After more than 36,500 health care workers at the University of California received at least one dose of vaccine, 71% of 379 workers with positive SARS-CoV-2 tests had positive results within 2 weeks after the first dose. Of 37 workers with positive results after the second dose, 7 had positive results 15 or more days after the dose.
May 06
-
Correspondence
SARS-CoV-2 Vaccine and Infection in Health Workers
J. Keehner and Others
-
-
Original Article
Treatment of MIS-C
A.J. McArdle and Others
An observational cohort study evaluated immunomodulatory therapy of multisystem inflammatory syndrome in children by comparing IVIG, IVIG plus glucocorticoids, or glucocorticoids alone. The investigators found no evidence of the superiority of any of the three therapies, although significant differences may emerge as more data accrue.
Jun 16Editorial Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
-
-
-
Original Article
MIS-C — Initial Therapy and Outcomes
M.B.F. Son and Others
An analysis of surveillance data on inpatients younger than 21 years of age who had multisystem inflammatory syndrome in children and were hospitalized between March 15 and October 31, 2020, showed that initial treatment with IVIG plus glucocorticoids was associated with a lower risk of cardiovascular dysfunction and a lower incidence of adjunctive therapy use than IVIG alone.
Jun 16 -
Original Article
Multisystem Inflammatory Syndrome in U.S. Children
L.R. Feldstein and Others
This report describes the epidemiology and clinical course of patients younger than 21 years of age from 26 states who had multisystem inflammatory syndrome. Many were infected with SARS-CoV-2 at least 1 to 2 weeks before syndrome onset. The median age of the patients was 8.3 years, and 73% were previously healthy.
Jul 23See Also Chinese Translation in NEJM 医学前沿
-
Original Article
MIS-C — Initial Therapy and Outcomes
M.B.F. Son and Others
-
-
Original Article
Tofacitinib for Covid-19 Pneumonia
P.O. Guimarães and Others
Patients who were hospitalized with Covid-19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group.
Jun 16
-
-
-
Original Article
Passive Immunotherapy in Patients with Covid-19
M.J. Joyner and Others
Among more than 3000 hospitalized patients with Covid-19, recipients of high-titer convalescent plasma had a lower mortality at 30 days than recipients of low-titer plasma. The effect of high-titer plasma was greatest in the subgroup of patients who were not receiving mechanical ventilation.
Mar 18Editorial (A Little) Clarity on Convalescent Plasma for Covid-19
-
Original Article
Convalescent Plasma in Early Covid-19 Infection
R. Libster and Others
High-titer convalescent plasma was compared with placebo in older adult patients within the first 3 days after the onset of symptoms of Covid-19 and documented SARS-CoV-2 infection. Disease progression was approximately half as common in patients who received convalescent plasma (16%) as in those who received placebo (31%).
Feb 18
-
Original Article
Passive Immunotherapy in Patients with Covid-19
M.J. Joyner and Others
-
-
Original Article
Interleukin-6 Receptor Blockade in Severe Covid-19
The REMAP-CAP Investigators
The interleukin-6 receptor blockers tocilizumab and sarilumab were tested against standard care in a randomized trial involving patients newly admitted to the intensive care unit and requiring respiratory or blood-pressure support. The median number of organ support–free days was 10 with tocilizumab, 11 with sarilumab, and 0 with standard care.
Feb 25Editorial Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
-
Original Article
Interleukin-6 Receptor Blockade in Severe Covid-19
The REMAP-CAP Investigators
-
-
Original Article
Tocilizumab in Severe Covid-19 Pneumonia
I.O. Rosas and Others
In this randomized trial involving 438 hospitalized patients with severe Covid-19 pneumonia, the use of the monoclonal antibody tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.
Feb 25
-
Original Article
Tocilizumab in Severe Covid-19 Pneumonia
I.O. Rosas and Others
-
-
Original Article
Dexamethasone Treatment in Covid-19
The RECOVERY Collaborative Group
Among hospitalized patients with Covid-19, treatment with dexamethasone resulted in lower 28-day mortality than usual care, according to the level of respiratory support the patients were receiving, indicating a possible correlation between efficacy and the stage of infection.
Feb 25Editorial Research in the Context of a Pandemic
Editorial The RECOVERY Platform -
Original Article
Neutralizing-Antibody Therapy in Covid-19
P. Chen and Others
In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%).
Jan 21Editorial Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
Original Article REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Correspondence Neutralizing Antibody LY-CoV555 for Outpatient Covid-19
-
Original Article
Dexamethasone Treatment in Covid-19
The RECOVERY Collaborative Group
-
-
Original Article
LY-CoV555 in Hospitalized Patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group
In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.
Mar 11Correspondence Monoclonal Antibody for Patients with Covid-19
-
Original Article
Antibody Cocktail in Early SARS-CoV-2 Infection
D.M. Weinreich and Others
An anti–SARS-CoV-2 antibody cocktail was given to patients within 3 days after PCR confirmation of Covid-19. In patients who were antibody-negative at baseline, treatment was associated with rapid viral clearance and potentially with a less frequent need for medical attention. The effect was less marked among patients who were antibody-positive at baseline.
Jan 21Original Article SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Editorial Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
-
Original Article
LY-CoV555 in Hospitalized Patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group
-
-
Original Article
Brief Report
VITT — Diagnosis and Treatment
A. Bourguignon and Others
A rare side effect of ChAdOx1 nCoV-19 vaccination against Covid-19 — venous or arterial thrombosis, which has been termed vaccine-induced immune thrombotic thrombocytopenia — has been reported in recent months. In this Brief Report, investigators describe the use of intravenous immune globulin in the treatment of three such vaccine recipients in Canada.
Jun 09
-
-
-
Correspondence
Rare Thromboembolic Events among Vaccinated South Africans
S. Takuva and Others
Among 288,368 South African health care workers who received the Ad26.COV2.S vaccine, no cases of vaccine-induced immune thrombotic thrombocytopenia have been observed, and the small number of thromboembolic events that have been noted occurred in persons with risk factors for thromboses other than vaccination.
Jun 02 -
Correspondence
Laboratory Method to Detect VITT
C. Vayne and Others
The rare vaccine-induced immune thrombotic thrombocytopenia that may follow adenovirus-based Covid-19 vaccination resembles heparin-induced thrombocytopenia, but rapid assays for anti-PF4 antibodies used to diagnose HIT may be negative in patients with VITT. The PF4–serotonin release assay appears to detect the IgG antibodies to PF4–PVS that mediate this condition.
May 19
-
Correspondence
Rare Thromboembolic Events among Vaccinated South Africans
S. Takuva and Others
-
-
Original Article
Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
M. Scully and Others
Scully and colleagues report 23 cases of abnormal clotting, primarily involving the cerebral veins, 6 to 24 days after the first dose of the ChAdOx1 nCoV-19 vaccine. The syndrome was incited by antibodies to platelet factor 4, independent of heparin therapy. Early recognition and avoidance of platelet transfusion are key.
Jun 10Editorial SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
-
Original Article
Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
M. Scully and Others
-
-
Original Article
Brief Report
ChAdOx1 nCoV-19 and Immune Thrombotic Thrombocytopenia
N.H. Schultz and Others
This report describes a very rare but life-threatening sequela of vaccination with ChAdOx1 nCoV-19. Within 10 days after a first injection, five health care workers presented with thrombocytopenia and thromboses, including cerebral venous sinus thrombosis with catastrophic outcome. The apparent cause is an anti-PF4 antibody capable of platelet activation; intravenous immune globulin may be therapeutic.
Jun 03Original Article Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
-
Original Article
Brief Report
ChAdOx1 nCoV-19 and Immune Thrombotic Thrombocytopenia
N.H. Schultz and Others
-
-
Original Article
Thrombosis after ChAdOx1 nCoV Vaccination
A. Greinacher and Others
In this case series, investigators report a very rare but life-threatening sequela of ChAdOx1 nCoV vaccination. Beginning 5 to 16 days after a first injection, some patients had symptoms consistent with thrombocytopenia, disseminated intravascular coagulation, and thromboses, including cerebral venous sinus thrombosis with catastrophic outcome. An anti–PF4 antibody capable of platelet activation appears to be the cause. Intravenous immune globulin may be therapeutic.
Apr 09
-
Original Article
Thrombosis after ChAdOx1 nCoV Vaccination
A. Greinacher and Others
-
-
Correspondence
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccine
K.-L. Muir and Others
A 48-year-old woman presented with a 3-day history of fatigue and abdominal pain 2 weeks after receiving the Ad26.COV2.S vaccine. She had a low platelet count and was found to have cerebral venous sinus thrombosis and clots in the right hepatic and splenic veins. Testing for antibody to PF4–polyanion was positive.
May 20
-
Correspondence
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccine
K.-L. Muir and Others
-
-
Original Article
BNT162b2 Vaccination against Covid-19 in 12-to-15-Year-Old Adolescents
R.W. Frenck, Jr., and Others
This randomized trial of the BNT162b2 vaccine involved 2260 adolescents 12 to 15 years of age. Similar levels of antibody to SARS-CoV-2 were elicited in the 12-to-15-year-old participants and in 16-to-25-year-old participants in a parallel trial. Among participants with no evidence of previous infection, no cases of Covid-19 were diagnosed in vaccine recipients, as compared with 16 cases in placebo recipients.
May 27
-
-
-
Clinical Implications of Basic Research
SARS-CoV-2 Vaccine Design
P.-A. Koenig and F.I. Schmidt
A recent study of the D614G variant spike protein of SARS-CoV-2 sheds light on a mechanism underlying the relatively increased infectivity of virions expressing it and has implications for vaccine design.
Jun 17 -
Correspondence
Local Covid-19 Vaccine Reactions in Non-White Persons
U. Samarakoon, S. Alvarez-Arango, and K.G. Blumenthal
Previous reports document a small risk of delayed large local reactions to Covid-19 vaccines; however, clinical photos most often show White persons. Reactions have also been noted in vaccine recipients who are Black, Indigenous, or People of Color (BIPOC). Photos of eight such delayed reactions are shown.
Jun 09
-
Clinical Implications of Basic Research
SARS-CoV-2 Vaccine Design
P.-A. Koenig and F.I. Schmidt
-
-
Original Article
Brief Report
Variant SARS-CoV-2 Infection after Vaccination
E. Hacisuleyman and Others
Mild Covid-19 symptoms developed in two fully vaccinated persons. Serum tests showed high titers of antibodies capable of neutralizing the wild-type strain of SARS-CoV-2 first identified in Wuhan, China, but sequencing of the virus isolates revealed novel variants. Some mutations in the receptor-binding domain of the spike protein were shared by the two variant strains.
Apr 21
-
Original Article
Brief Report
Variant SARS-CoV-2 Infection after Vaccination
E. Hacisuleyman and Others
-
-
Correspondence
Vaccination and SARS-CoV-2 Infection in Nursing Homes
E.M. White and Others
The authors examined incident SARS-CoV-2 infection after mRNA vaccination among residents of 280 nursing homes. A total of 18,242 residents received at least one dose, and 13,048 received both. Infection incidence decreased from 4.5% after the first dose to 0.3% after the second dose. Most infections were asymptomatic, and the incidence of both symptomatic and asymptomatic infections decreased.
May 19
-
Correspondence
Vaccination and SARS-CoV-2 Infection in Nursing Homes
E.M. White and Others
-
-
Original Article
mRNA Covid-19 Vaccine Safety in Pregnant Persons
T.T. Shimabukuro and Others
Preliminary data from the CDC “v-safe after vaccination health checker” surveillance system, the v-safe pregnancy registry, and the Vaccine Adverse Event Reporting System did not show any obvious safety signals among pregnant persons who received mRNA Covid-19 vaccines. More data are needed to better inform maternal, pregnancy, and infant outcomes.
Jun 17Editorial mRNA Covid-19 Vaccines in Pregnant Women
-
Original Article
mRNA Covid-19 Vaccine Safety in Pregnant Persons
T.T. Shimabukuro and Others
-
-
Correspondence
Neutralization of SARS-CoV-2 Variants by Convalescent and Vaccinee Serum
G.-L. Wang and Others
Serum samples from patients convalescing after SARS-CoV-2 infection and after vaccination with BBIBP-CorV or CoronaVac in China neutralized pseudoviruses expressing spike proteins from the B.1.1.7 variant at levels that were similar to those from the wild-type (Wuhan) isolate but lower than those from the B.1.351 variant.
Jun 17
-
Correspondence
Neutralization of SARS-CoV-2 Variants by Convalescent and Vaccinee Serum
G.-L. Wang and Others
-
-
Original Article
NVX-CoV2373 Vaccine Efficacy against B.1.351 in South Africa
V. Shinde and Others
A randomized, phase 2 trial compared the NVX-CoV2373 nanoparticle vaccine with placebo in participants in South Africa, including 30% who were seropositive at baseline. Overall vaccine efficacy was 49.4%, with the B.1.351 variant identified in more than 90% of isolates.
May 05Editorial Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control
-
-
-
Correspondence
BNT162b2 Vaccine and Emerging SARS-CoV-2 Variants
Y. Liu and Others
A total of 20 serum samples from 15 persons who received the BNT162b2 vaccine showed strong neutralization activity against recombinant viruses engineered to express the spike protein from the Wuhan-Hu-1 strain and B.1.429, B.1.526, and B.1.1.7 variants. These in vitro neutralization assays are not clearly predictive of activity in vivo.
May 12 -
Original Article
Efficacy of the ChAdOx1 Vaccine against the B.1.351 Variant
S.A. Madhi and Others
A double-blind randomized trial in South Africa documented poor efficacy of two doses of the ChAdOx1 nCoV-19 vaccine against the B.1.351 variant of SARS-CoV-2 that emerged in South Africa. Infections occurred in 3.2% of placebo recipients and in 2.5% of vaccine recipients. Thirty-nine of the 42 virus isolates were the B.1.351 variant. None of the cases led to hospitalization or death.
May 20Editorial Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control
-
Correspondence
BNT162b2 Vaccine and Emerging SARS-CoV-2 Variants
Y. Liu and Others
-
-
Clinical Practice
Mild or Moderate Covid-19
R.T. Gandhi, J.B. Lynch, and C. del Rio
The diagnosis of Covid-19 is usually based on SARS-CoV-2 PCR testing of a nasopharyngeal swab or other specimen. Remdesivir and dexamethasone have benefits in hospitalized patients with severe Covid-19, but in patients with moderate disease, dexamethasone is not efficacious and data are insufficient to recommend for or against routine use of remdesivir.
Oct 29
-
-
-
Perspective
Protecting Olympic Participants from Covid-19
A.K. Sparrow and Others
Plans to protect participants and the public from Covid-19 during the Olympics aren’t built on rigorous risk assessment. They fail to consider the ways in which exposure occurs, the factors that contribute to exposure, and which participants may be at highest risk.
May 25 -
Clinical Practice
Severe Covid-19
D.A. Berlin, R.M. Gulick, and F.J. Martinez
Patients with severe Covid-19 should be closely monitored regarding the need for endotracheal intubation; intubated patients should receive lung-protective ventilation. Data from randomized, controlled trials are awaited to inform the use of antiviral and immunomodulatory therapies; preliminary data support benefits of remdesivir in this population.
May 15See Also Chinese Translation in NEJM 医学前沿
-
Perspective
Protecting Olympic Participants from Covid-19
A.K. Sparrow and Others
-
-
Original Article
Antibodies and SARS-CoV-2 Infection in Health Workers
S.F. Lumley and Others
In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.
Dec 23
-
-
-
Correspondence
Cross-Reactive Antibody Responses Elicited by the 501Y.V2 Variant
T. Moyo-Gwete and Others
Convalescent serum from persons who had recovered from infection with 501Y.V2 (B.1.351), a SARS-CoV-2 variant first identified in South Africa, showed potent neutralization of the original variant (D614G), the 501Y.V2 variant, and the P.1 variant first identified in Brazil. These results suggest that vaccines based on the 501Y.V2 spike protein may be broadly effective against two common variants of SARS-CoV-2.
Apr 07 -
Correspondence
Duration of Positive SARS-CoV-2 on RT-PCR and Culture
M.-C. Kim and Others
In 21 consecutive patients with confirmed Covid-19, the median times from symptom onset to negative viral culture and negative real-time RT-PCR were 7 days and 34 days, respectively. The longest interval from symptom onset and from resolution of fever to positive culture was 12 days and 3 days, respectively.
Feb 18Correspondence Viable SARS-CoV-2 Shedding
See Also Chinese Translation in NEJM 医学前沿
-
Correspondence
Cross-Reactive Antibody Responses Elicited by the 501Y.V2 Variant
T. Moyo-Gwete and Others
-
-
Correspondence
Shedding of SARS-CoV-2 after Immunosuppression
T. Aydillo and Others
The prolonged contagious period after viral infection in immunocompromised patients may affect how long precautions will be necessary to reduce further transmission. Replication-competent SARS-CoV-2 was detected for up to 61 days in patients who were immunocompromised by treatment for cancer.
Dec 24
-
Correspondence
Shedding of SARS-CoV-2 after Immunosuppression
T. Aydillo and Others
-
-
Original Article
Durable Humoral Response to SARS-CoV-2
D.F. Gudbjartsson and Others
This large comparative study of the Icelandic population showed that the humoral response did not decline within 4 months after infection, that 44% of persons who had been infected had not been diagnosed with qPCR, and that the infection fatality risk was 0.3%.
Oct 29Editorial The Power of Antibody-Based Surveillance
-
Original Article
Durable Humoral Response to SARS-CoV-2
D.F. Gudbjartsson and Others
-
-
Videos in Clinical Medicine
Emergency Intubation in Covid-19
G.S. Shrestha and Others
This video demonstrates the procedure for emergency endotracheal intubation in patients with suspected or proven Covid-19. Endotracheal intubation in such patients poses a risk of infection for the health care personnel involved. Meticulous planning and preparation and the use of practice drills can minimize this risk.
Feb 18Letters responding to this article are now published: Emergency Intubation in Covid-19
-
-
-
Videos in Clinical Medicine
Percutaneous Tracheostomy
D.A. Hashimoto, A.L. Axtell, and H.G. Auchincloss
A tracheostomy is a surgically created airway that is kept open with a breathing tube, or tracheostomy tube. This video demonstrates percutaneous tracheostomy, a procedure that may be performed at the patient’s bedside, including patients with Covid-19, who may require a tracheostomy in the course of severe respiratory distress.
Oct 28Correspondence Percutaneous Tracheostomy
-
Videos in Clinical Medicine
Family Meetings on Behalf of Patients with Serious Illness
E. Widera and Others
Effective family meetings build rapport and offer support, provide updates about a patient’s medical status and prognosis, and ensure treatment that is consistent with the patient’s goals. Such meetings can result in better use of health care resources. This video demonstrates how to have an effective family meeting.
Sep 10
-
Videos in Clinical Medicine
Percutaneous Tracheostomy
D.A. Hashimoto, A.L. Axtell, and H.G. Auchincloss
-
-
Perspective
SARS-CoV-2 Testing and School Reopening
Y. Rafiei and M.M. Mello
Most U.S. school reopening plans focus on screening for Covid-19 symptoms. But because an estimated 40% of Covid-19 cases are asymptomatic and 50% of transmissions occur from asymptomatic persons, screening testing is critical.
Dec 03 -
Correspondence
Detection of SARS-CoV-2 with a CRISPR-Based Test
J. Joung and Others
A new method for the detection of SARS-CoV-2 combines simplified extraction of RNA with isothermal amplification and CRISPR (clustered regularly interspaced short palindromic repeats)–mediated detection. Testing of 402 samples indicated a sensitivity of 93.1% and a specificity of 98.5%.
Oct 08
-
Perspective
SARS-CoV-2 Testing and School Reopening
Y. Rafiei and M.M. Mello
-
-
Videos in Clinical Medicine
How to Obtain a Nasopharyngeal Swab Specimen
F.M. Marty, K. Chen, and K.A. Verrill
Collecting specimens from the surface of the respiratory mucosa with nasopharyngeal swabs is a procedure used to diagnose Covid-19 as well as other respiratory viral infections and certain bacterial infections in adults and children. This video describes the collection of specimens for detection of Covid-19.
May 28Correspondence How to Obtain a Nasopharyngeal Swab SpecimenSee Also Chinese Translation in NEJM 医学前沿
-
-
-
Correspondence
Patient-Collected Swabs for SARS-CoV-2 Testing
Y.-P. Tu and Others
Tongue, nasal, and mid-turbinate swabs to detect SARS-CoV-2 were collected by 530 outpatients before a health care worker collected nasopharyngeal swabs from these patients. Both the mid-turbinate and the nasal samples collected by the patients themselves may be clinically acceptable, with estimated sensitivities above 90%.
Jul 30
-
Correspondence
Patient-Collected Swabs for SARS-CoV-2 Testing
Y.-P. Tu and Others
-
-
Correspondence
Saliva Specimens to Detect SARS-CoV-2 Infection
A.L. Wyllie and Others
In this letter, the investigators report that saliva specimens and nasopharyngeal swab specimens had similar sensitivity in the detection of SARS-CoV-2 RNA in both symptomatic and asymptomatic persons.
Sep 24Correspondence Saliva for Detection of SARS-CoV-2
-
Correspondence
Saliva Specimens to Detect SARS-CoV-2 Infection
A.L. Wyllie and Others
-
-
Correspondence
Microvascular Changes in the Brain in Covid-19
M.-H. Lee and Others
High-resolution MRI and histopathological study of the brains of patients who had died from Covid-19 showed punctate hyperintensities and punctate or linear hypointensities, which represented various forms of pauci-inflammatory microvasculopathy. No evidence of active viral infection was found.
Dec 30 -
Original Article
Nimble GWAS on Covid-19
The Severe Covid-19 GWAS Group
During the peak of hospitalizations of patients with severe Covid-19 in Italy and Spain in March, a group of researchers in these and other countries obtained and analyzed samples, resulting in the identification of two chromosomal loci associated with the disorder.
Oct 15Editorial Genetic Risk of Severe Covid-19
Correspondence Mining a GWAS of Severe Covid-19See Also Chinese Translation in NEJM 医学前沿
-
Correspondence
Microvascular Changes in the Brain in Covid-19
M.-H. Lee and Others
-
-
Review Article
Cytokine Storm
D.C. Fajgenbaum and C.H. June
Cytokine storm, a life-threatening disorder involving cytokine elevations and immune-cell hyperactivation, has various causes and is characterized by constitutional symptoms, systemic inflammation, and multiorgan dysfunction. Selective interventions can ameliorate the illness.
Dec 03See Also Chinese Translation in NEJM 医学前沿
-
-
-
Original Article
Baricitinib plus Remdesivir for Adults with Covid-19
A.C. Kalil and Others
In a trial involving 1033 patients hospitalized with Covid-19, the addition of baricitinib to remdesivir was associated with shorter recovery time, particularly among patients receiving high-flow oxygen, and with a 30% higher odds of improvement at day 15 than remdesivir alone. Adverse events were less frequent with the combination therapy.
Dec 11
-
-
-
Original Article
Repurposed Antiviral Drugs for Covid-19
WHO Solidarity Trial Consortium
The authors report interim results of the WHO Solidarity trial of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with Covid-19. Effects on overall mortality, initiation of ventilation, and duration of hospital stay are compared.
Dec 02Editorial A Large, Simple Trial Leading to Complex Questions
Perspective FDA Approval of Remdesivir — A Step in the Right Direction -
Original Article
Remdesivir for Covid-19 — Final Report
J.H. Beigel and Others
In this randomized, double-blind trial in 1062 adults hospitalized with Covid-19, remdesivir was superior to placebo in shortening the time to recovery (10 days, vs. 15 days with placebo). The estimates of mortality by day 29 were 11.4% with remdesivir and 15.2% with placebo. The benefit of remdesivir was most apparent in patients who were receiving low-flow oxygen at baseline.
Nov 05Correspondence Remdesivir for the Treatment of Covid-19 — Preliminary Report
See Also Chinese Translation in NEJM 医学前沿
-
Original Article
Repurposed Antiviral Drugs for Covid-19
WHO Solidarity Trial Consortium
-
-
Original Article
Remdesivir for 5 Days or 10 Days in Covid-19
J.D. Goldman and Others
A randomized trial comparing a 5-day course of intravenous remdesivir with a 10-day course in patients with Covid-19 pneumonia and hypoxemia who were not yet receiving mechanical ventilation showed no significant differences in outcome related to the duration of treatment.
Nov 05Editorial Remdesivir — An Important First Step
-
Original Article
Remdesivir for 5 Days or 10 Days in Covid-19
J.D. Goldman and Others
-
-
Original Article
Compassionate-Use Remdesivir for Severe Covid-19
J. Grein and Others
A cohort of patients with severe Covid-19 received treatment with remdesivir under a compassionate-use protocol. Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 18 days.
Jun 11See Also Chinese Translation in NEJM 医学前沿
-
Original Article
Compassionate-Use Remdesivir for Severe Covid-19
J. Grein and Others
-
-
Case Records of the Massachusetts General Hospital
A Man with Headache and Covid-19
H.M. Heller and Others
A 24-year-old man was admitted to the hospital with a 3-week history of headache and a positive test for SARS-CoV-2 RNA. MRI showed multiple small hyperintense foci in the caudate nuclei and putamina. On lumbar puncture, the opening pressure was higher than 55 cm of water; the CSF white-cell count was 108 per microliter. What is the diagnosis?
Dec 24 -
Correspondence
SARS-CoV-2 in an Immunocompromised Host
B. Choi and Others
This letter describes an immunocompromised patient who had persistent infection with SARS-CoV-2 over a period of months, despite several courses of remdesivir. Phylogenetic analysis showed accelerated viral evolution.
Nov 11
-
Case Records of the Massachusetts General Hospital
A Man with Headache and Covid-19
H.M. Heller and Others
-
-
Case Records of the Massachusetts General Hospital
A Woman with Chest Pain, Dyspnea, and Shock
C. Newton-Cheh and Others
A 44-year-old woman presented with cough, dyspnea, and chest pain. On examination, she had tachycardia and hypotension. Evaluation revealed SARS-CoV-2 RNA in a nasopharyngeal swab, as well as elevated levels of troponin and lactic acid and a decline in urine output. Urgent management decisions were made.
Jul 30
-
-
-
Correspondence
Type I Interferonopathy in Muscle in a Man with Covid-19
G.S. Manzano, J.K. Woods, and A.A. Amato
Generalized, predominantly proximal weakness and a greatly elevated creatine kinase level developed in a man with Covid-19. Immunohistochemical analysis of a muscle-biopsy specimen revealed abnormal expression of MHC-1 and myxovirus resistance protein A on muscle fibers, suggesting type I interferonopathy.
Dec 10
-
Correspondence
Type I Interferonopathy in Muscle in a Man with Covid-19
G.S. Manzano, J.K. Woods, and A.A. Amato
-
-
Case Records of the Massachusetts General Hospital
A Woman Who Died from Covid-19
J.R. Stone and Others
A 76-year-old woman was admitted to the hospital with confusion and hypoxemia. Multiple residents at her assisted-living facility had received a diagnosis of Covid-19. Testing of a nasopharyngeal swab was positive for SARS-CoV-2. On the fourth hospital day, respiratory distress developed; 36 hours later, the patient died. An autopsy was performed.
Jul 23
-
Case Records of the Massachusetts General Hospital
A Woman Who Died from Covid-19
J.R. Stone and Others
-
-
Medicine and Society
Tribal Truce
L. Rosenbaum
Since human behavior — including wearing or shunning masks — will determine the ultimate toll of the Covid-19 pandemic, communication strategies that bridge our partisan divide over science may prove as important as any novel therapeutic.
Sep 23 -
Perspective
Facial Masking for Covid-19
M. Gandhi and G.W. Rutherford
Increasing the proportion of SARS-CoV-2 infections that are asymptomatic with the simple public health measure of universal masking might help make the infection less deadly and increase population-level immunity without severe illnesses and deaths.
Sep 08Correspondence Facial Masking for Covid-19
-
Medicine and Society
Tribal Truce
L. Rosenbaum
-
-
Videos in Clinical Medicine
Personal Protective Equipment and Covid-19
R. Ortega and Others
This video demonstrates a procedure for donning and doffing one type of PPE recommended by the CDC for use in hospitals to minimize the risk of exposure to infectious material during the care of patients with Covid-19.
Jun 25Correspondence Personal Protective Equipment and Covid-19
-
-
-
Correspondence
Universal Masking in the Covid-19 Era
M. Klompas, C.A. Morris, and E.S. Shenoy
Klompas and colleagues write that they understand that some people are citing their Perspective article (published on April 1) as support for discrediting widespread masking. In truth, the intent of their article was to push for more masking, not less.
Jul 09Perspective Universal Masking in Hospitals in the Covid-19 Era
-
Correspondence
Universal Masking in the Covid-19 Era
M. Klompas, C.A. Morris, and E.S. Shenoy
-
-
Sounding Board
Allocating Scarce Medical Resources for Covid-19
E.J. Emanuel and Others
The Covid-19 pandemic has already stressed health care systems throughout the world, requiring rationing of medical equipment and care. The authors discuss the ethical values relevant to health care rationing and provide six recommendations to guide fair allocation of scarce medical resources during the pandemic.
May 21Perspective The Toughest Triage — Allocating Ventilators in a Pandemic
Correspondence Allocating Medical Resources in the Time of Covid-19
-
Sounding Board
Allocating Scarce Medical Resources for Covid-19
E.J. Emanuel and Others

